ArticleBMC biology2026
Circular RNA dynamics in breast-to-brain metastatic cascade.
Article in BMC biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundBreast-to-brain metastases (BTB mets) represent one of the most aggressive and clinically challenging manifestations of breast cancer. The limited efficacy of available therapies and poor patient outcomes reflect the intricate molecular and cellular processes underlying metastatic colonization of the brain. The molecular events driving this process involve extensive transcriptomic reprogramming, encompassing not only protein-coding genes but also diverse classes of non-coding RNAs. Circular RNAs (circRNAs) are a distinct class of stable, non-coding transcripts increasingly recognized as key regulators of cancer biology, yet their role in brain-tropic metastasis remains poorly defined. This study aimed to systematically profile circRNA expression across primary tumors and metastatic sites to uncover regulatory mechanisms and define site-specific circRNA expression patterns associated with BTB mets.
resultsCircRNAs displayed highly site-specific expression patterns during metastatic breast cancer progression. Notably, the majority of differentially expressed circRNAs were uncoupled from changes in their linear host genes, highlighting transcriptionally-independent circularization as a regulatory mechanism. Notably, the majority of circRNAs distinguishing BTB mets from primary breast tumors and pleural effusions likewise distinguished them from primary brain tumors (glioblastoma). Analysis of the circRNA landscape revealed 42 circRNAs that are consistently deregulated and characteristic of BTB mets. Subsequent functional analysis of circRNA-microRNA interactions revealed that these circRNAs are enriched in metastatic signaling pathways and brain-related biological processes, suggesting a potential role for circRNA-mediated regulation in adaptation to the brain microenvironment. Additionally, circRNA landscapes exhibit high stability under conditions that promote either stemness or differentiation. To support data exploration, Breast circScope (circrna.netlify.app), an open-access resource that enables analysis of circRNA expression and host gene associations, along with curated visualization tools, was developed.
conclusionsPresented findings uncover a previously unrecognized dimension of post-transcriptomic regulation in metastatic breast cancer, demonstrating that circRNAs exhibit site-specific expression patterns associated with metastatic progression. These results highlight circRNAs as integral molecules in the regulatory landscape of breast cancer metastasis and provide a framework for understanding their functional contribution to brain-tropic disease.
Indexed as
Identifiers
42415096What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.